Overexpression of androgen receptor enhances the binding of the receptor to the chromatin in prostate cancer

Oncogene

Volumn 31, Issue 17, 2012, Pages 2153-2163

  Urbanucci, A ^a   Sahu, B ^b   Seppala J ^c   Larjo, A ^c   Latonen, L M ^a   Waltering, K K ^a   Tammela, T L J ^c   Vessella, R L ^d   Lahdesmaki H ^e   Janne O A ^b   Visakorpi, T ^a  

^a TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

^c TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^d UNIVERSITY OF WASHINGTON   (United States)

^e AALTO UNIVERSITY   (Finland)

Author keywords

AR; ChIP seq; FEN1; prostatic neoplasia; SKP2; ZWINT

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; LIGAND; S PHASE KINASE ASSOCIATED PROTEIN 2; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR SLUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CASTRATION RESISTANT PROSTATE CANCER; CELL STRAIN LNCAP; CHROMATIN; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; GENE AMPLIFICATION; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATECTOMY; PROTEIN EXPRESSION; RECEPTOR BINDING; TUMOR XENOGRAFT;

ANIMALS; BINDING SITES; CELL LINE, TUMOR; CHROMATIN; FLAP ENDONUCLEASES; GENE AMPLIFICATION; GENE EXPRESSION PROFILING; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MICE; NUCLEAR PROTEINS; NUCLEIC ACID AMPLIFICATION TECHNIQUES; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; S-PHASE KINASE-ASSOCIATED PROTEINS; TRANSPLANTATION, HETEROLOGOUS;

EID: 84860311841     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2011.401     Document Type: Article

References (53)

1. Abramoff MD, Magelhaes PJ, Ram SJ. (2004). Image Processing with ImageJ. Biophotonics Int 11: 36-42.
2. Andriole GL, Bostwick DG, Brawley OW, Gomella LG, Marberger M, Montorsi F. et al. (2010). Effect of dutasteride on the risk of prostate cancer. N Engl J Med 362: 1192-1202.
3. Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R. et al. (2004). Molecular determinants of resistance to antiandrogen therapy. Nat Med 10: 33-39.
4. Cleutjens KBJM, van der Korput HAGM, van Eekelen CCEM, van Rooij HCJ, Faber PW, Trapman J. (1997). An androgen response element in a far upstream enhancer region is essential for high, androgen-regulated activity of the prostate-specific antigen promoter. Mol Endocrinol 11: 148-161.
5. Huggins C, Hodges CV. (2002). Studies on prostatic cancer, I: the effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate 1941. J Urol 168: 9-12.
6. Isaacs JT. (1994). Role of androgens in prostatic cancer. Vitam Horm 49: 433-502.
7. Jia L, Berman BP, Jariwala U, Yan X, Cogan JP, Walters A. et al. (2008). Genomic androgen receptor-occupied regions with different functions, defined by histone acetylation, coregulators and transcriptional capacity. PLoS One 3: e3645.
8. Kang Z, Jänne OA, Palvimo JJ. (2004). Coregulator recruitment and histone modifications in transcriptional regulation by the androgen receptor. Mol Endocrinol 11: 2633-2648.
9. Karvonen U, Kallio PJ, Jänne OA, Palvimo JJ. (1997). Interaction of androgen receptors with androgen response element in intact cells. J Biol Chem 272: 15973-15979.
10. Kasowski M, Grubert F, Heffelfinger C, Hariharan M, Asabere A, Waszak SM. et al. (2010). Variation in transcription factor binding among humans. Science 328: 232-235.
11. Keller A, Backes C, Al-Awadhi M, Gerasch A, Kü ntzer J, Kohlbacher O. et al. (2008). GeneTrailExpress: a web-based pipeline for the statistical evaluation of microarray experiments. BMC Bioinformatics 9: 552.
12. Kokontis JM, Hay N, Liao S. (1998). Progression of LNCaP prostate tumor cells during androgen deprivation: hormone-independent growth, repression of proliferation by androgen, and role for p27kip1 in androgen-induced cell cycle arrest. Mol Endocrinol 12: 941-953.
13. Kops GJ, Kim Y, Weaver BA, Mao Y, McLeod I, Yates III JR. et al. (2005). ZW10 links mitotic checkpoint signaling to the structural kinetochore. J Cell Biol 169: 49-60.
14. Lam JS, Seligson DB, Yu H, Li A, Eeva M, Pantuck AJ. et al. (2006). Flap endonuclease 1 is overexpressed in prostate cancer and is associated with a high Gleason score. BJU Int 98: 445-451.
15. Leinonen KA, Tolonen TT, Bracken H, Stenman UH, Tammela TL, Saramä ki OR. et al. (2010). Association of SPINK1 expression and TMPRSS2:ERG fusion with prognosis in endocrine-treated prostate cancer. Clin Cancer Res 16: 2845-2851.
16. Lin HK, Chen Z, Wang G, Nardella C, Lee SW, Chan CH. et al. (2010). Skp2 targeting suppresses tumorigenesis by Arf-p53-independent cellular senescence. Nature 464: 374-379.
17. Lin YT, Chen Y, Wu G, Lee WH. (2006). Hec1 sequentially recruits Zwint-1 and ZW10 to kinetochores for faithful chromosome segregation and spindle checkpoint control. Oncogene 25: 6901-6914.
18. Linja MJ, Savinainen KJ, Saramä ki OR, Tammela TL, Vessella RL, Visakorpi T. (2001). Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Res 61: 3550-3555.
19. Lupien M, Eeckhoute J, Meyer CA, Wang Q, Zhang Y, Li W. et al. (2008). FoxA1 translates epigenetic signatures into enhancer-driven lineage-specific transcription. Cell 132: 958-970.
20. Massie CE, Adryan B, Barbosa-Morais NL, Lynch AG, Tran MG, Neal DE. et al. (2007). New androgen receptor genomic targets show an interaction with the ETS1 transcription factor. EMBO Rep 8: 871-878.
21. Massie CE, Lynch A, Ramos-Montoya A, Boren J, Stark R, Fazli L. et al. (2011). The androgen receptor fuels prostate cancer by regulating central metabolism and biosynthesis. EMBO J 30: 2719.
22. Matys V, Kel-Margoulis OV, Fricke E, Liebich I, Land S, Barre-Dirrie A. et al. (2006). TRANSFAC(r) and its module TRANSCompel(r): transcriptional gene regulation in eukaryotes. Nucleic Acids Res 34: D108-D110.
23. Nakayama KI, Nakayama K. (2006). Ubiquitin ligases: cell-cycle control and cancer. Nat Rev Cancer 6: 369-381.
24. Nguyen PL, Lin DI, Lei J, Fiorentino M, Mueller E, Weinstein MH. et al. (2011). The impact of Skp2 overexpression on recurrencefree survival following radical prostatectomy. Urol Oncol 29: 302-308.
25. Obuse C, Iwasaki O, Kiyomitsu T, Goshima G, Toyoda Y, Yanagida M. (2004). A conserved Mis12 centromere complex is linked to heterochromatic HP1 and outer kinetochore protein Zwint-1. Nat Cell Biol 6: 1135-1141.
26. Reid AH, Attard G, Danila DC, Oommen NB, Olmos D, Fong PC. et al. (2010). Significant and sustained antitumor activity in postdocetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. J Clin Oncol 28: 1489-1495.
27. Roudier MP, Corey E, True LD, Higano CS, Ott SM, Vessella RL. (2004). Histological, immunophenotypic and histomorphometric characterization of prostate cancer bone metastases. In: Keller E, Chung L (eds). The Biology of Skeletal Metastases vol. 118. Kluwer Academic Publishers: Boston, MA, USA, pp 311-339.
28. Schuur ER, Henderson GA, Kmetec LA, Miller JD, Lamparski HG, Henderson DR. (1996). Prostate-specific antigen expression is regulated by an upstream enhancer. J Biol Chem 271: 7043-7051.
29. Seruga B, Ocana A, Tannock IF. (2011). Drug resistance in metastatic castration-resistant prostate cancer. Nat Rev Clin Oncol 8: 12-23.
30. Sharma A, Yeow WS, Ertel A, Coleman I, Clegg N, Thangavel C. et al. (2010). The retinoblastoma tumor suppressor controls androgen signaling and human prostate cancer progression. J Clin Invest 120: 4478-4492.
31. Starr DA, Saffery R, Li Z, Simpson AE, Choo KH, Yen TJ. et al. (2000). HZwint-1, a novel human kinetochore component that interacts with HZW10. J Cell Sci 113: 1939-1950.
32. Takayama K, Tsutsumi S, Katayama S, Okayama T, Horie-Inoue K, Ikeda K. et al. (2010). Integration of cap analysis of gene expression and chromatin immunoprecipitation analysis on array reveals genome-wide androgen receptor signaling in prostate cancer cells. Oncogene 30: 619-630.
33. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS. et al. (2010). Integrative genomic profiling of human prostate cancer. Cancer Cell 18: 11-22.
34. Thiery JP. (2002). Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 6: 442-454.
35. Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG. et al. (2003). The influence of finasteride on the development of prostate cancer. N Engl J Med 349: 215-224.
36. Thompson J, Lepikhova T, Teixido-Travesa N, Whitehead MA, Palvimo JJ, Jänne OA. (2006). Small carboxyl-terminal domain phosphatase 2 attenuates androgen-dependent transcription. EMBO J 25: 2757-2767.
37. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW. et al. (2005). Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310: 644-648.
38. Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, Arora V. et al. (2009 Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 324: 787-790.
39. Urbanucci A, Waltering KK, Suikki HE, Helenius MA, Visakorpi T. (2008). Androgen regulation of the androgen receptor coregulators. BMC Cancer 8: 219.
40. Visakorpi T, Hyytinen E, Koivisto P, Tanner M, Keinänen R, Palmberg C. et al. (1995). In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet 9: 401-406.
41. Waltering KK, Helenius MA, Sahu B, Manni V, Linja MJ, Jänne OA. et al. (2009). Increased expression of androgen receptor sensitizes prostate cancer cells to low levels of androgens. Cancer Res 69: 8141-8149.
42. Waltering KK, Porkka KP, Jalava SE, Urbanucci A, Kohonen P, Latonen L. et al. (2011). Androgen regulation of microRNAs in prostate cancer. Prostate 71: 604-614.
43. Waltregny D, Leav I, Signoretti S, Soung P, Lin D, Merk F. et al. (2001). Androgen-driven prostate epithelial cell proliferation and differentiation in vivo involve the regulation of p27. Mol Endocrinol 15: 765-782.
44. Wang D, Garcia-Bassets I, Benner C, Li W, Su X, Zhou Y. et al. (2011). Reprogramming transcription by distinct classes of enhancers functionally defined by eRNA. Nature 474: 390-394.
45. Wang Q, Carroll JS, Brown M. (2005). Spatial and temporal recruitment of androgen receptor and its coactivatos involves chromosomal looping and polymerase tracking. Mol Cell 19: 631-642.
46. Wang Q, Li W, Liu XS, Carroll JS, Jänne OA, Keeton EK. et al. (2007). A hierarchical network of transcription factors governs androgen receptor-dependent prostate cancer growth. Mol Cell 27: 380-392.
47. Wang Q, Li W, Zhang Y, Yuan X, Xu K, Yu J. et al. (2009). Androgen receptor regulates a distinct transcription program in androgenindependent prostate cancer. Cell 138: 245-256.
48. Wei GH, Badis G, Berger MF, Kivioja T, Palin K, Enge M. et al. (2010). Genome-wide analysis of ETS-family DNA-binding in vitro and in vivo. EMBO J 29: 2147-2160.
49. Xu H, Zheng L, Dai H, Zhou M, Hua Y, Shen B. (2011). Chemicalinduced cancer incidence and underlying mechanisms in Fen1 mutant mice. Oncogene 30: 1072-1081.
50. Yu J, Yu J, Mani RS, Cao Q, Brenner CJ, Cao X. et al. (2010). An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression. Cancer Cell 17: 443-445.
51. Zheng L, Dai H, Zhou M, Li M, Singh P, Qiu J. et al. (2007). Fen1 mutations result in autoimmunity, chronic inflammation and cancers. Nat Med 13: 812-819.
52. Zheng L, Jia J, David Finger L, Guo Z, Zer C, Shen B. (2010). Functional regulation of FEN1 nuclease and its link to cancer. Nucleic Acids Res 39: 781-794.
53. Zinzen RP, Girardot C, Gagneur J, Braun M, Furlong EE. (2009). Combinatorial binding predicts spatio-temporal cis-regulatory activity. Nature 462: 65-70.